News

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.

Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

The oral S1P receptor modulator has promise to break new ground for disease modification.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

COVID-19 patients receiving at least 2 antibiotics were at a higher CDI risk.

New research over 2 decades shows patients with opioid use disorder are often prescribed opioid analgesic prior to OUD diagnosis, although rates have decreased in recent years.

Dr. Jennifer Payne discusses how the events of the last year has impacted her patients and what needs to happen to improve mental health care in the future.

The 2021 annual report finds that Los Angeles remains the most polluted US city, while negative impacts of climate change and COVID-19 are both linked to increased pollution rates.

The odds of suicidal behavior was 49% lower for OUD patients receiving substance use disorder treatment.

New data show female veterans receive poorer secondary prevention care in treating premature and extremely premature atherosclerotic cardiovascular disease, compared to male veterans.

An expert writes on the value of shared knowledge into the intricacies of allergic risks.

Direct-acting antivirals have been a major milestone in the treatment of hepatitis C virus, new data show they also work in nearly all children, without serious adverse events.

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

Recent data finds children treated for allergies with ≥14 consecutive days of corticosteroids experienced greater incidence rates than those not treated with a corticosteroid.